Cystic fibrosis infections: Treatment strategies and prospects

George, AM; Jones, PM; Middleton, PG

Cystic fibrosis infections: Treatment strategies and prospects

George, AM

Jones, PM Middleton, PG

Permalink

Publication Type:: Journal Article
Citation:: FEMS Microbiology Letters, 2009, 300 (2), pp. 153 - 164
Issue Date:: 2009-11-01

Closed Access

	Filename	Description	Size
	2008007486OK.pdf		893.48 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	George, AM https://orcid.org/0000-0003-4691-8960	en_US
dc.contributor.author	Jones, PM	en_US
dc.contributor.author	Middleton, PG	en_US
dc.date.issued	2009-11-01	en_US
dc.identifier.citation	FEMS Microbiology Letters, 2009, 300 (2), pp. 153 - 164	en_US
dc.identifier.issn	0378-1097	en_US
dc.identifier.uri	http://hdl.handle.net/10453/8661
dc.description.abstract	Pseudomonas aeruginosa and Burkholderia cepacia are the two major Gram-negative rods that colonize/infect the lungs of patients with cystic fibrosis (CF). These organisms may cause progressive respiratory failure, although occasionally more rapid infections result in the 'Cepacia' syndrome. Many antibiotics have been used against Pseudomonas and Burkholderia, but once chronic colonization has been established, eradication of these organisms is rare. Drug therapy for CF patients is compromised by a number of bacterial factors that render the infectious agents resistant to antibiotics, including efflux pumps that remove antibiotics, lack of penetration of antibiotics into bacterial biofilms, and changes in the cell envelope that reduce the permeability of antibiotics. Any combination of these mechanisms increases the likelihood of bacterial survival. Therefore, combinations of antibiotics or of antibiotic and nonantibiotic compounds are currently being tested against Pseudomonas and Burkholderia. However, progress has been slow, with only occasional combinations showing promise for the eradication of persistent Gram-negative rods in the airways of CF patients. This review will summarize the current knowledge of CF infections and speculate on potential future pathways to treat these chronic infections. © 2009 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd.	en_US
dc.relation.ispartof	FEMS Microbiology Letters	en_US
dc.relation.isbasedon	10.1111/j.1574-6968.2009.01704.x	en_US
dc.subject.classification	Microbiology	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Burkholderia Infections	en_US
dc.subject.mesh	Pseudomonas Infections	en_US
dc.subject.mesh	Cystic Fibrosis	en_US
dc.subject.mesh	Bronchopneumonia	en_US
dc.subject.mesh	Anti-Bacterial Agents	en_US
dc.subject.mesh	Drug Therapy, Combination	en_US
dc.subject.mesh	Drug Resistance, Bacterial	en_US
dc.title	Cystic fibrosis infections: Treatment strategies and prospects	en_US
dc.type	Journal Article
utslib.citation.volume	2	en_US
utslib.citation.volume	300	en_US
utslib.for	0605 Microbiology	en_US
utslib.for	06 Biological Sciences	en_US
utslib.for	07 Agricultural and Veterinary Sciences	en_US
utslib.for	11 Medical and Health Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access
pubs.issue	2	en_US
pubs.publication-status	Published	en_US
pubs.volume	300	en_US

Abstract:

Pseudomonas aeruginosa and Burkholderia cepacia are the two major Gram-negative rods that colonize/infect the lungs of patients with cystic fibrosis (CF). These organisms may cause progressive respiratory failure, although occasionally more rapid infections result in the 'Cepacia' syndrome. Many antibiotics have been used against Pseudomonas and Burkholderia, but once chronic colonization has been established, eradication of these organisms is rare. Drug therapy for CF patients is compromised by a number of bacterial factors that render the infectious agents resistant to antibiotics, including efflux pumps that remove antibiotics, lack of penetration of antibiotics into bacterial biofilms, and changes in the cell envelope that reduce the permeability of antibiotics. Any combination of these mechanisms increases the likelihood of bacterial survival. Therefore, combinations of antibiotics or of antibiotic and nonantibiotic compounds are currently being tested against Pseudomonas and Burkholderia. However, progress has been slow, with only occasional combinations showing promise for the eradication of persistent Gram-negative rods in the airways of CF patients. This review will summarize the current knowledge of CF infections and speculate on potential future pathways to treat these chronic infections. © 2009 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/8661